North America Blood Screening Market

North America Blood Screening Market Size (2023 to 2032)

The North America Blood Screening Market was valued at USD 0.85 billion in 2023. The North America Blood Screening Market is expected to have 10.1 % CAGR from 2024 to 2032 and be worth USD 2.02  billion by 2032 from USD 0.94 billion in 2024.  

A few of the significant factors promoting the blood screening market in the North American region are the vast pool of patients, improved healthcare infrastructure, increasing disposable income, growing demand for donated blood, and growing government support. On the other hand, increasing awareness of the importance of maintaining the safety of donated blood, the rising prevalence of infectious diseases, and the growing demand for donated blood are majorly contributing to the market growth. 

In Addition, new technological advancements in blood screening, major market key players, increased healthcare concern, and a rising number of initiators like initiatives taken by the government are expected to propel the market growth. 

However, alternative technologies, such as digital immunoassay and a scarcity of qualified workers, are projected to restrain the North American blood screening market growth during the forecast period. Also, the Complex regulatory frameworks for approval, a shortage of experienced labor, competing technologies such as digital immunoassay, and expensive initial capital investment and testing expenses further limit the blood screening market growth.

This research report on the North American blood screening market has been segmented and sub-segmented into the following categories

North America Blood Screening Market - By Technology

• Nucleic Acid Amplification

• Elisa

• Rapid Test
• NGS
• Western Blotting

North America Blood Screening Market - By Product

• Instruments

• Reagent & Kits

• Software

North America Blood Screening Market - By End User

• Blood banks

• Hospital

North America Blood Screening Market - By Country

• The United States

• Canada

• Rest of North America

Based on the region, the market is exhibiting obvious potential in the specified forecast period. As of 2023, North America leads the global blood screening market with a share of 41%. The North American blood screening market is anticipated to account for the largest share in the global market during the forecast period due to the technical developments in blood screening technologies and the region's rising incidence of infectious diseases.  

Currently, North America is the leader among all the regions in the blood screening market owing to the rising demand for donated blood, the increasing number of blood donors, the proliferation of infectious diseases across the region. In Addition, the increase in the prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players are fuelling the market growth. 

KEY MARKET PLAYERS

A few of the promising companies operating in the North America blood screening market profiled in the report are Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Ortho Clinical Diagnostics, Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche Ltd, Grifols, Siemens AG and Beckman Coulter, Inc.